US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older

The FDA has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for adults 65 and older, as well as those aged 12-64 with underlying risk factors, marking the first approval since the agency tightened requirements for COVID vaccine approvals. Moderna expects the refrigerator-stable vaccine to be available for the 2025-2026 respiratory virus season, with late-stage trial data showing non-inferior efficacy compared to its original Spikevax vaccine and superior efficacy in adults over 18. This approval comes as Moderna navigates declining demand for its original COVID vaccine and increased regulatory scrutiny under the Department of Health and Human Services.

Analysis

Moderna (MRNA.O) has secured U.S. Food and Drug Administration (FDA) approval for its next-generation COVID-19 vaccine, mNEXSPIKE, specifically for adults aged 65 and older, and individuals aged 12 to 64 with at least one underlying risk factor. This marks the first such endorsement since the FDA implemented stricter requirements for COVID vaccine approvals, with Moderna anticipating mNEXSPIKE's availability for the 2025-2026 respiratory virus season. Crucially, late-stage trial data indicated mNEXSPIKE's non-inferiority to Spikevax in individuals aged 12 years and older, and superior efficacy compared to Spikevax in adults 18 years and older. The vaccine's refrigerator stability, offering longer shelf life and easier distribution, presents a significant logistical advantage, particularly for developing nations. This approval is strategically vital for Moderna as it navigates waning demand for its original Spikevax vaccine and lower-than-expected uptake of its respiratory syncytial virus (RSV) vaccine. The regulatory environment remains dynamic, with the Department of Health and Human Services under Robert F. Kennedy Jr. intensifying scrutiny, and the FDA mandating placebo-controlled trials for COVID booster shots in healthy adults under 65, effectively limiting their application to older adults and at-risk groups. However, the Centers for Disease Control and Prevention (CDC) affirmed that COVID vaccines remain an option for healthy children by agreement between parents and doctors, a stance which has somewhat eased investor concerns by maintaining the existing framework for older and at-risk populations who typically seek these vaccinations.

Key Decisions for Investors

• The FDA approval of mNEXSPIKE is a positive catalyst for Moderna, offering a potential revenue stream to mitigate declining Spikevax sales and demonstrating pipeline progress; investors should assess its impact on forward earnings estimates.
• Monitor the commercial launch strategy and subsequent market uptake of mNEXSPIKE during the 2025-2026 season, as its performance will be critical in validating Moderna's next-generation mRNA platform and market positioning.
• Remain cognizant of the heightened regulatory scrutiny and evolving FDA requirements for COVID-19 vaccines, as these factors could influence future product approvals, market access, and overall investment risk in Moderna.
• Evaluate the potential for mNEXSPIKE's enhanced storage and distribution characteristics to expand market reach, particularly in developing countries, which could offer incremental growth opportunities if effectively capitalized upon.